Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and i...
Oct 24, 2025, 4:00 AM EDT - 1 day ago
Jul 1, 2025, 5:00 AM EDT - 4 months ago
May 8, 2025, 7:00 AM EDT - 6 months ago
May 7, 2025, 7:00 AM EDT - 6 months ago
Apr 15, 2025, 5:00 AM EDT - 6 months ago
Mar 19, 2025, 9:28 AM EDT - 7 months ago
Jan 28, 2025, 8:01 AM EST - 9 months ago
Jan 9, 2025, 6:00 AM EST - 10 months ago
Jan 8, 2025, 3:17 PM EST - 10 months ago
Oct 23, 2024, 7:00 AM EDT - 1 year ago
Oct 2, 2024, 6:30 AM EDT - 1 year ago
May 6, 2024, 6:25 AM EDT - 1 year ago
Feb 8, 2024, 5:00 AM EST - 1 year ago
Sep 6, 2023, 7:00 AM EDT - 2 years ago
Jul 28, 2023, 3:00 AM EDT - 2 years ago
Jun 29, 2023, 7:00 AM EDT - 2 years ago
Apr 26, 2023, 7:00 AM EDT - 2 years ago
Apr 3, 2023, 7:00 AM EDT - 2 years ago
Mar 2, 2023, 6:45 AM EST - 2 years ago
Feb 7, 2023, 7:00 AM EST - 2 years ago
Nov 7, 2022, 8:05 AM EST - 3 years ago
Oct 24, 2022, 7:30 AM EDT - 3 years ago
Sep 7, 2022, 7:00 AM EDT - 3 years ago
Jul 25, 2022, 6:00 AM EDT - 3 years ago
May 13, 2022, 7:30 AM EDT - 3 years ago
May 9, 2022, 7:30 AM EDT - 3 years ago
May 4, 2022, 4:30 PM EDT - 3 years ago
May 4, 2022, 7:30 AM EDT - 3 years ago
May 2, 2022, 4:30 PM EDT - 3 years ago
Apr 27, 2022, 7:30 AM EDT - 3 years ago
Apr 20, 2022, 7:30 AM EDT - 3 years ago
Mar 9, 2022, 7:46 AM EST - 3 years ago
Feb 24, 2022, 7:30 AM EST - 3 years ago
Dec 17, 2021, 4:15 PM EST - 4 years ago
Dec 14, 2021, 10:36 PM EST - 4 years ago